Literature DB >> 2335239

Mechanisms of differential regulation of interleukin-6 mRNA accumulation by tumor necrosis factor alpha and lymphotoxin during monocytic differentiation.

M A Brach1, N A Cicco, D Riedel, T Hirano, T Kishimoto, R H Mertelsmann, F Herrmann.   

Abstract

In the present report we compare the capacity of two related cytokines, tumor necrosis factor (TNF) alpha and lymphotoxin (LT), to modulate mRNA levels of interleukin-6 (IL-6) in cells representing different stages of monocytic differentiation including the human leukemia cell lines HL 60, U 937, THP-1, MonoMac 1 and peripheral blood monocytes. We show that the capacity of TNF alpha and LT to induce IL-6 mRNA accumulation increases as monocytic differentiation proceeds with TNF alpha being more potent than LT, suggesting that alternate pathways may be used by differentiating cells to control expression of IL-6. In contrast, in monocytes which constitutively synthesize IL-6 transcripts, TNF alpha and LT treatment had opposite effects on levels of IL-6 mRNA accumulation. In these cells TNF alpha enhanced steady state levels of IL-6 transcripts due to mRNA stabilization, whereas LT shortened IL-6 mRNA half-life, most likely due to induction of a RNA destabilizer since LT-mediated downregulation of levels of IL-6 mRNA in monocytes could be prevented by inhibition of protein synthesis. Neither TNF alpha nor LT altered IL-6 mRNA accumulation by interfering with preexisting transcription factors since both TNF alpha and LT required de novo protein synthesis to exert their effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335239     DOI: 10.1016/0014-5793(90)81411-g

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons.

Authors:  P G Murphy; L S Borthwick; R S Johnston; G Kuchel; P M Richardson
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

2.  High interleukin-6 plasma levels in acute promyelocytic leukemia.

Authors:  R Stasi; A Venditti; G del Poeta; M Tribalto; U Coppetelli; G Zaccari; G Papa
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

3.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.

Authors:  C M Ausiello; F Urbani; S Gessani; G C Spagnoli; M J Gomez; A Cassone
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

5.  Rapid cytokine up-regulation of integrins, complement receptor 1 and HLA-DR on monocytes but not on lymphocytes.

Authors:  G A Limb; A S Hamblin; R A Wolstencroft; D C Dumonde
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

6.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 7.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.